actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284
Generic: Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284
actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284: 1 clinical trial tracked.
actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about actinium ac 225-dota-anti-steap2 monoclonal antibody azd2284, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Number of participants with adverse event (AEs)
Interventionalopen136 targetStarted 2025-03Completion 2029-0416 sites · Australia, South Africa, United StatesAstraZeneca